Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « conventional »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
convalescent < conventional < conversely  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 25.
[0-20] [0 - 20][0 - 25][20-24][20-40]
Ident.Authors (with country if any)Title
000023 (2020) Yehyun Park [Corée du Sud] ; Jae Hee Cheon [Corée du Sud]Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
000079 (2020) Caterina Vacchi [Italie] ; Marco Sebastiani [Italie] ; Giulia Cassone [Italie] ; Stefania Cerri [Italie] ; Giovanni Della Casa [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review
000091 (2020) Guillaume Decarriere [France] ; Thomas Barnetche [France] ; Bernard Combe [France] ; Cécile Gaujoux-Viala [France] ; Cédric Lukas [France] ; Jacques Morel [France] ; Claire Daien [France]The most appropriate conventional DMARD to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis.
000118 (2020) Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000143 (2020) Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica]Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
000151 (2020) Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
000164 (2020) Giulia Cassone ; Andreina Manfredi ; Fabiola Atzeni ; Vincenzo Venerito ; Caterina Vacchi ; Valentina Picerno ; Federica Furini ; Gian Luca Erre ; Paola Tomietto ; Anna Laura Fedele [Italie] ; Giovanni Della Casa [Italie] ; Valeria Nucera ; Chiara Giannitti [Italie] ; Carlo Salvarani ; Marco SebastianiSafety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
000166 (2020) Elyes Bouajina [Tunisie] ; Leith Zakraoui [Tunisie] ; Montassar Kchir [Tunisie] ; Samir Kochbati [Tunisie] ; Sofiene Baklouti [Tunisie]Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
000178 (2020) Adelaide Sofia Batalha Figueiredo [Portugal] ; Ana Luísa Oliveira [Portugal] ; Ant Nio Caetano [Portugal] ; Maria Francisca Moraes-Fontes [Portugal]SAPHO: has the time come for tailored therapy?
000183 (2020) Ibai Los-Arcos [Espagne] ; Juan Aguilar-Company [Espagne] ; Isabel Ruiz-Camps [Espagne]Risk of infection associated with new therapies for lymphoproliferative syndromes.
000214 (2020) Alyson W. Wong [Canada] ; Christopher J. Ryerson [Canada] ; Sabina A. Guler [Suisse]Progression of fibrosing interstitial lung disease
000244 (2020) Przemysław Błyszczuk [Suisse, Pologne] ; Zoltan Szekanecz [Hongrie]Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis
000311 (2020) Durga Prasanna Misra [Inde] ; Sakir Ahmed [Inde] ; Vikas Agarwal [Inde]Is biological therapy in systemic sclerosis the answer?
000339 (2020) Hsin-Yun Sun [Taïwan] ; Jann-Yuan Wang [Taïwan] ; Yee-Chun Chen [Taïwan] ; Po-Ren Hsueh [Taïwan] ; Yi-Hsuan Chen [Taïwan] ; Yu-Chung Chuang [Taïwan] ; Chi-Tai Fang [Taïwan] ; Shan-Chwen Chang [Taïwan] ; Jung-Der Wang [Taïwan]Impact of introducing fluorescent microscopy on hospital tuberculosis control: A before-after study at a high caseload medical center in Taiwan
000367 (2020) Charlotte Hua [France] ; Frank Buttgereit [Allemagne] ; Bernard Combe [France]Glucocorticoids in rheumatoid arthritis: current status and future studies
000387 (2020) Jeffrey P. Jacobs [États-Unis] ; Alfred H. Stammers [États-Unis] ; James St Louis [États-Unis] ; J W Awori Hayanga [États-Unis] ; Michael S. Firstenberg [États-Unis] ; Linda B. Mongero [États-Unis] ; Eric A. Tesdahl [États-Unis] ; Keshava Rajagopal [États-Unis] ; Faisal H. Cheema [États-Unis] ; Tom Coley [États-Unis] ; Vinay Badhwar [États-Unis] ; Anthony K. Sestokas [États-Unis] ; Marvin J. Slepian [États-Unis]Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.
000394 (2020) Alberto Meneguzzo ; Annalisa Lazzarotto ; Mauro AlaibacEruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer
000417 (2020) Matthijs S. Van Der Leeuw [Pays-Bas] ; Paco M. J. Welsing [Pays-Bas] ; Maria J. H. De Hair [Pays-Bas] ; Johannes W. G. Jacobs [Pays-Bas] ; Anne C. A. Marijnissen [Pays-Bas] ; Suzanne P. Linn-Rasker [Pays-Bas] ; Faouzia Fodili [Pays-Bas] ; Reinhard Bos [Pays-Bas] ; Janneke Tekstra [Pays-Bas] ; Jacob M. Van Laar [Pays-Bas]Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
000424 (2020) Salah Ghabri [France] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Franck Maunoury [France] ; J Jaime Caro [États-Unis]Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
000439 (2020) L. Baganz [Allemagne] ; J. Listing [Allemagne] ; J. Kekow [Allemagne] ; C. Eisterhues [Allemagne] ; S. Wassenberg [Allemagne] ; A. Zink [Allemagne] ; A. Strangfeld [Allemagne]Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
000469 (2020) Jehun Song [Corée du Sud] ; Seongmin Kang [Corée du Sud] ; Seung Won Choi [Corée du Sud] ; Kwang Won Seo [Corée du Sud] ; Sunggun Lee [Corée du Sud] ; Min Wook So [Corée du Sud] ; Doo-Ho Lim [Corée du Sud]Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "conventional" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "conventional" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    conventional
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021